CRSingapore 2025 Organizing Committee: | Controlled Release Society (CRS)

RWTH Aachen University Clinic Germany	Twan Lammers, DSc, Ph.D. Twan Lammers obtained a DSc in Radiation Oncology from Heidelberg University in 2008 and a PhD in Pharmaceutical Technology from Utrecht University in 2009. The same year, he started the Nanomedicine and Theranostics group at RWTH Aachen University. In 2014, he was promoted to full professor of medicine at RWTH Aachen University Clinic. His group aims to individualize and improve disease treatment by combining drug targeting with imaging. He is included in the Clarivate Analytics list of Highly Cited Researchers. He serves as the past president of the Controlled Release Society and council member of the European Society for Molecular Imaging.
Assistant ProfessorNational University of Singapore Yong Loo Lin School of Medicine Singapore	Jiong-Wei Wang, Ph.D. Jiong-Wei Wang received his Ph.D. in Medicine in 2013 from the Leiden University Medical Centre. After a brief postdoctoral training in the University Medical Centre Utrecht, he moved to the National University of Singapore (NUS). He was promoted to Assistant Professor in 2019 at NUS Yong Loo Lin School of Medicine Department of Surgery, with joint appoints at the Department of Physiology and the Cardiovascular Research Institute. His current research focus on cardiovascular immunology and preclinical development of nanomedicine with natural and/or synthetic nanoparticle systems for the treatment of inflammatory, cardiovascular disease and metabolic diseases including fatty liver disease.
Utrecht University / National University of Singapore / Ayuvant Inc. Netherlands	Gert Storm, Ph.D. Gert Storm is a (bio)pharmaceutical scientist specializing in Targeted Nanopharmaceuticals. He is an emeritus professor at Utrecht University and the University of Twente in The Netherlands and a visiting research professor at the Department of Surgery at the National University of Singapore. He is co-founder of the companies Eden Ophthalmic in Singapore and Ayuvant in Utrecht, scientific advisor at Liposoma in Amsterdam, vice-president of the Phospholipid Research Center in Heidelberg, board member of the European Foundation for Clinical Nanomedicine in Basel and member of APV Focus Group Drug Delivery in Mainz. He is (co-)author of > 650 publications (H-index 125, Google Scholar, December 2023) and since 2014 included in the Highly Cited Researcher lists of Clarivate Analytics (Researcher ID: O-8696-2016).
i3S - Instituto de Investigação e Inovação em Saúde, University of Porto Portugal	Bruno Sarmento, Ph.D. Bruno Sarmento is the Principal Investigator, Group Leader, and member of the Board of Directors at i3S – University of Porto. Bruno Sarmento is also invited as an Associate Professor at IUCS-CESPU. His research is focused on developing functionalized nanomedicines, namely nanoformulations for mucosal and target delivery. He has also specialized in 3D tissue engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlations. He published 500 papers in international journals (total citations in Scopus 22000; H-index 76). Bruno Sarmento was the first Chair of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society (CRS) and is now Secretary of CRS and a member of CRS College of Fellows.
Purdue University United States	Professor Yoon Yeo, Ph.D. Prof. Yoon Yeo is the Lillian Barboul Thomas Professor and Associate Department Head of Industrial and Molecular Pharmaceutics at Purdue University. She has built expertise in pharmaceutical sciences and drug delivery through Ph.D. training in protein microencapsulation and post-doc training in hydrogel-based biomaterials. At Purdue, Prof. Yeo leads a research program specializing in immunomodulatory formulations for anti-inflammatory applications and cancer immunotherapy, intracellular delivery of gene therapeutics and peptide antibiotics, new methods of delivering anticancer drugs, and long-acting drug delivery systems, with the support of the NIH, NSF, and industry. She has authored >130 peer-reviewed papers with an h-index of 62 and >13000 citations. Prof. Yeo is a Fellow of the American Association of Pharmaceutical Scientists (AAPS, 2019) and the Controlled Release Society (CRS, 2022) and currently serves as a Deputy Editor-in-Chief of the Journal of Controlled Release and for the CRS Board of Directors (2023-2026). She received the NSF CAREER award (2011), New Investigator Awards from the AAPS (2009), and American Association of Colleges of Pharmacy (2008).
National University of Singapore Singapore	Linda Hong, Ph.D. Linda Hong, Ph.D is a lecturer at the National University of Singapore. She specializes in pharmaceutical technology. Her research interests consist of lipid-based nano-delivery systems and small-angle scattering
RWTH Aachen University, Germany	Yang Shi, Ph.D. Yang Shi, Ph.D is a Full Professor and Head of the Department of Polymer Therapeutics in the Faculty of Medicine at RWTH Aachen University, Germany. Dr. Shi obtained his PhD degree from Utrecht University in 2014 on polymeric micelles for tumor-targeted drug delivery. Afterwards, he held positions as Associate Professor at South China University of Technology and Group Leader at RWTH Aachen University. Currently, his group focuses on engineering and understanding polymer-based therapeutic systems for chemotherapy, vaccination, and immunotherapy. He has received funding support from the European Research Council (ERC, Starting Grant; Proof of Concept Grant), the German Research Foundation (DFG), and the Federal Ministry of Education and Research (BMBF). His work has received awards and fellowship, including Science Award (International Pharma Sciences Foundation/Rottendorf Stiftung), Rising Star Awards from leading publisher groups (American Chemical Society and Springer Nature), Merck Best Talk Award (Controlled Release Society) and Theodore von Kármán Fellow (RWTH and Harvard). He is serving as an Editor for the Journal of Controlled Release and the Journal of Nanobiotechnology.
National University of Singapore Singapore	Giorgia Pastorin, MSc, Ph.D. Giorgia Pastorin received her MSc degree in Pharmaceutical Chemistry and Technology in 2000 and her Ph.D. in 2004 from the University of Trieste (Italy). She spent two years of her postgraduate training at the CNRS in Strasbourg (France), where she specialized in drug delivery. She joined the National University of Singapore (NUS) in June 2006, as an Assistant Professor in the Department of Pharmacy-Faculty of Science. She was promoted to Associate Professor in 2011 and Full Professor in 2024; she is currently the Head of the Department of Pharmacy & Pharmaceuticals Sciences, Faculty of Science, NUS. Her main research interests include the exploitation of nanobiomaterials, such as cell-derived nanovesicles (CDNs) or nano-cell-vesicle technologies (nCVTs), as targeted drug delivery strategies utilizing surface functionalizations and design of novel platinum-based pro-drugs. She is the main inventor in several US patents, provisional patents, and invention disclosures. For the work performed by her BioNano-technology (BNT) group, she received both university and international awards.
National University of Singapore Singapore	Matthias G. Wacker, Ph.D. Associate Professor Matthias G. Wacker of the National University of Singapore specializes in pharmaceutical technology and nanosciences. He earned his doctoral degree from Goethe University Frankfurt, where he also completed his habilitation and served as a principal investigator. Before joining NUS, he led the Department of Pharmaceutical Technology and Nanosciences at Fraunhofer IME. His research focuses on using quality-by-design approaches to develop advanced dosage forms, emphasizing bio-predictive release and in vitro-in vivo correlations. He serves on editorial boards of prominent journals and has received multiple awards, including the Eudragit® Best Paper Award and the Phoenix Pharmaceutics Science Award.